As Dr Ashley Bloomfield swaps being pulse of the nation for luxury robes and erotic fanfiction, seems Redditors agree on something; shopping may be our collective addiction. And Amazon’s (AMZN) not mad about it. 🛒 The tech giant and shopping mecca last week surpassed even analysts’ ‘rosy’ expectations. This despite a turbulent year that included a 20-for-1 stock split and new CEO Andy Jassy’s first year on the tools. But could it be Amazon’s own add-to-cart moment that’s caught investors attention?  

Since announcing Amazon’s proposed purchase of app-based primary care provider One Medical (ONEM) for US$3.9 billion in an all-cash deal this July, both companies' share prices have lifted. While the deal’s being triaged behind screens, the Amazon Health Services team has hinted at defibrillating the US’s endemic health delays, with health care ‘high on the list of experiences that need reinvention’. More rural MRIs ahead, perhaps? 👨‍⚕️ 

So is Teladoc Health (TDOC) reaching for the laughing gas? Following another disappointing earnings quarter, and having slumped 87.5% from their February 2021 high, Amazon’s proposed cash injection in the health sector may have hearts racing. 🩺 Yet despite Teladoc’s plummet stinging, ARK doesn’t plan to amputate the largest US virtual healthcare provider from their Genomic Revolution ETF (ARKG). And Cathie Wood continues to back problem-solving innovation in the ‘genomic age’. 🧬

While the ETF hasn’t had investors in stitches, falling 56.32% since August last year, it rallied this June thanks to top contributors, biochemical analysis tech company 908 Devices (MASS) and gene-editing companies Crispr Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) - which this year secured ‘renowned’ Harvard stem cell researcher Doug Melton to head up type 1 diabetes research. 🌡️ Only time will tell if they’re enough to cure the dis-ease.